In Vivo MRSI of Hyperpolarized [1-13C]Pyruvate Metabolism in Rat Hepatocellular Carcinoma


Darpolor, M. M., Yen, Y. F., Chua, M. S., Xing, L., Clarke‐Katzenberg, R. H., Shi, W., … & Spielman, D. M. (2011). In vivo MRSI of hyperpolarized [1‐13C] pyruvate metabolism in rat hepatocellular carcinoma. NMR in Biomedicine, 24(5), 506-513.


Hepatocellular carcinoma (HCC), the primary form of human adult liver malignancy, is a highly aggressive tumor with average survival rates that are currently less than 1 year following diagnosis. Most patients with HCC are diagnosed at an advanced stage, and no efficient marker exists for the prediction of prognosis and/or response(s) to therapy. We have reported previously a high level of [1-13C]alanine in an orthotopic HCC using single-voxel hyperpolarized [1-13C]pyruvate MRS. In the present study, we implemented a three-dimensional MRSI sequence to investigate this potential hallmark of cellular metabolism in rat livers bearing HCC (n = 7 buffalo rats). In addition, quantitative real-time polymerase chain reaction was used to determine the mRNA levels of lactate dehydrogenase A, nicotinamide adenine (phosphate) dinucleotide dehydrogenase quinone 1 and alanine transaminase. The enzyme levels were significantly higher in tumor than in normal liver tissues within each rat, and were associated with the in vivo MRSI signal of [1-13C]alanine and [1-13C]lactate after a bolus intravenous injection of [1-13C]pyruvate. Histopathological analysis of these tumors confirmed the successful growth of HCC as a nodule in buffalo rat livers, revealing malignancy and hypervascular architecture. More importantly, the results demonstrated that the metabolic fate of [1-13C]pyruvate conversion to [1-13C]alanine significantly superseded that of [1-13C]pyruvate conversion to [1-13C]lactate, potentially serving as a marker of HCC tumors. Copyright © 2010 John Wiley & Sons, Ltd.

Read more from SRI